A British study highlights the potential benefits of medical cannabis in improving anxiety, sleep quality, and overall quality of life for ADHD patients, with minimal and moderate side effects reported. The findings suggest a need for further research into cannabis use for ADHD treatment, taking into consideration the diverse effects of different cannabis strains and consumption patterns.
A study conducted by a team of British scientists provides new evidence of the potential benefits of medical cannabis for individuals with ADHD.
In this rare research published in Psychopharmacology Reports, 12 patients with ADHD who were using medical cannabis were observed over a period. Improvements in anxiety, sleep quality, and overall health-related quality of life were noted. Additionally, the patients tolerated cannabis well: less than one-fifth reported negative side effects, most of which were moderate.
The authors of the study claim that these results, although not conclusive, provide reasons for future research into the use of cannabis in treating ADHD.
For more news like this, along with all the latest in legalization, research, and lifestyle, download our free cannabis news app.
ADHD, or Attention Deficit Hyperactivity Disorder, is a neurodevelopmental condition characterized by problems with attention span, hyperactivity, and impulsiveness. Although traditionally classified as a disorder, many experts now define it as a type of neurodiversity (a natural human diversity in the way different brains process information).
From this perspective, ADHD presents unique benefits such as creative thinking, high energy levels, and hyper-focus. However, the diagnosis also comes with a range of difficulties: not just issues with concentration, hyperactivity, and impulsiveness, but also a higher risk of sleep problems, anxiety, and depression. These challenges can negatively affect quality of life, education, work, and social relationships.
Data from 2022 shows that over 10% of the population suffers from ADHD. Although some medications have been effective in alleviating ADHD symptoms (such as Adderall, Ritalin, or Wellbutrin), many of them cause negative side effects. Due to the risk of effects such as reduced appetite, insomnia, emotional regulation disorders, irritability, and adverse cardiovascular events, many individuals diagnosed with ADHD avoid these medications.
Cannabis is known for activating the endocannabinoid system, which, according to preclinical studies, may be impaired in individuals with ADHD. Additional research suggests that cannabis may help increase concentration, motivation, learning abilities, memory, and reduce hyperactivity, thought clutter, and impulsiveness in individuals with ADHD.
However, other studies have observed that cannabis may worsen cognitive functions in ADHD patients. These conflicting findings indicate the need for further, in-depth research to understand the real impact of cannabis on ADHD.
To investigate the long-term effects of cannabis use in individuals with ADHD, scientists in the discussed study analyzed data from 68 ADHD patients from the British Medical Cannabis Registry. Eighty percent of the patients had previously used cannabis.
Analyzing patient-reported outcome measures (as well as daily doses of CBD and THC) at 1, 3, 6, and 12-month intervals, it was found that levels of anxiety, sleep quality, and overall health-related quality of life improved.
Only 11 out of 68 participants reported any negative side effects. Nine patients actually stopped taking other ADHD medications during treatment. Importantly, anxiety and sleep quality indicators improved at each subsequent measurement throughout the 12-month period. Significant improvements were also observed in the overall quality of life related to health in the first 6 months of the study. However, after 12 months, these improvements returned to baseline levels – with no significant difference between patients who had previously used cannabis and those who had not.
Scientists also noted some moderate negative side effects: the most common were insomnia, concentration disorders, lethargy, and dry mouth. Nevertheless, only 11 out of 68 participants reported any negative side effects.
The new study adds detail to the research on cannabis in the treatment of ADHD. Scientists extracted data from real patients using cannabis, as opposed to data from population studies or experiments on cells or animals.
However, this study has certain limitations. First and foremost, it cannot prove that cannabis caused the observed improvements; it might only be a correlation. Moreover, scientists did not examine the different effects resulting from various cannabis use patterns: not just dosing, but also the chemical components of different strains and consumption methods. Therefore, each of these patterns requires a separate study. We cannot assume that all cannabis varieties will yield the same results.
The study mainly involved men (80.88%), which may lead to an overrepresentation of cannabis’s impact on men with ADHD. Future studies should consider how cannabis might affect male and female patients with ADHD differently.
Overall, this study shows strong evidence that cannabis can benefit individuals with ADHD, especially in terms of alleviating anxiety and sleep disorders associated with the condition. However, further research is needed to confirm these findings and determine the best ways to use cannabis for these purposes. If you are interested in using cannabis to treat ADHD, consult a cannabis clinic specializing in medical cannabis treatment.
—
(Featured image by Tara Winstead via Pexels)
DISCLAIMER: This article was written by a third-party contributor and does not reflect the opinion of Hemp.im, its management, staff, or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the company may believe that its expectations are based on reasonable assumptions, the actual results that the company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in Fakty Konopne, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
The DEA has postponed a key hearing on the reclassification of cannabis. The hearing was…
A new California Department of Public Health report has come out with recommendations for THC…
Ontario is investing $31 million over the next three years to enhance efforts against illegal…
Frankfurt and Hanover are launching five-year pilot projects for legal, regulated cannabis sales to adults,…
Italy's Regional Administrative Court suspended the Health Ministry's decree labeling CBD as a narcotic, pending…
This November, five U.S. states will vote on measures related to legalizing recreational or medical…